Martine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction dated Wednesday, July 8th. The shares were sold at an average price of $553.17, for a total transaction of $5,255,115.00. Following the sale, the chief executive officer owned 40,513 shares in the company, valued at approximately $22,410,576.21. This trade represents a 19.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

United Therapeutics Trading Down 0.3%

NASDAQ:UTHR traded down $1.86 during mid-day trading on Thursday, hitting $552.48. The company’s stock had a trading volume of 294,071 shares, compared to its average volume of 494,403. The company has a market capitalization of $23.45 billion, a price-to-earnings ratio of 20.39, a P/E/G ratio of 1.85 and a beta of 0.58. United Therapeutics Corporation has a fifty-two week low of $272.12 and a fifty-two week high of $609.35. The stock has a fifty day moving average of $557.51 and a 200-day moving average of $529.07.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The company had revenue of $781.50 million for the quarter, compared to analyst estimates of $797.40 million. During the same period in the previous year, the firm posted $6.63 earnings per share. The firm’s revenue for the quarter was down 1.6% compared to the same quarter last year. On average, equities analysts anticipate that United Therapeutics Corporation will post 26.63 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently commented on UTHR. Cantor Fitzgerald boosted their price target on United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a research note on Thursday, March 12th. Bank of America increased their price objective on United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a research note on Tuesday, March 31st. TD Cowen reissued a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. HC Wainwright boosted their target price on shares of United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a research note on Tuesday, March 31st. Finally, Morgan Stanley set a $516.00 target price on shares of United Therapeutics in a report on Thursday, May 7th. Ten equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $646.00.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the company. Torren Management LLC bought a new stake in United Therapeutics during the 4th quarter worth approximately $26,000. Activest Wealth Management raised its position in United Therapeutics by 1,400.0% in the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 56 shares during the last quarter. WealthCollab LLC boosted its stake in United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 38 shares in the last quarter. Rakuten Securities Inc. boosted its stake in United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 46 shares in the last quarter. Finally, Entrust Financial LLC bought a new stake in shares of United Therapeutics during the fourth quarter worth $31,000. Institutional investors own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.